Skip to main content
Erschienen in: Die Gynäkologie 9/2011

01.09.2011 | Leitthema

Vulvakarzinom – bei weitem kein ungefährliches Alterskarzinom

Moderne Therapieoptionen

verfasst von: Prof. Dr. M. Hampl, G. Bauerschmitz, W. Janni

Erschienen in: Die Gynäkologie | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Vulvakarzinom ist nicht mehr ein Alterskarzinom: Die Zunahme dieser Tumorentität um 300–400% in der letzten Dekade ist vor allem durch das gehäufte Auftreten dieser Tumoren bei jungen Frauen bedingt. Abhängig vom Alter der Patientin ist an diesen Tumoren in 30–60% eine Infektion mit humanen Papillomviren (HPV) ursächlich beteiligt. Die Prädilektionsstelle ist die Region zwischen Klitoris und Urethra (etwa 40%). Die Behandlung ist die Resektion in sano oder (partielle) Vulvektomie und eine inguinofemorale Lymphknotenentfernung. Als neue Therapieoptionen ist die Sentinel-Lymphonodektomie und die Deckung des Defektes mit lokoregionären Lappen zur Verbesserung des ästhetischen wie des funktionellen Ergebnisses zu sehen.
Literatur
1.
Zurück zum Zitat http://www.krebsinfo.de/ki/epi-daten/pdf/inz2001.pdf http://www.krebsinfo.de/ki/epi-daten/pdf/inz2001.pdf
2.
Zurück zum Zitat Engel JS-FG, Hölzel D (2001) Epidemiologie. In: Kimmig: Tumormanual Vulvakarzinom, Zuckschwerdt, München, S 1–4 Engel JS-FG, Hölzel D (2001) Epidemiologie. In: Kimmig: Tumormanual Vulvakarzinom, Zuckschwerdt, München, S 1–4
3.
Zurück zum Zitat Al-Ghamdi A, Freedman D, Miller D et al (2002) Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 84:94–101PubMedCrossRef Al-Ghamdi A, Freedman D, Miller D et al (2002) Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 84:94–101PubMedCrossRef
4.
Zurück zum Zitat Carter J, Carlson J, Fowler J et al (1993) Invasive vulvar tumors in young women–a disease of the immunosuppressed? Gynecol Oncol 51:307–310PubMedCrossRef Carter J, Carlson J, Fowler J et al (1993) Invasive vulvar tumors in young women–a disease of the immunosuppressed? Gynecol Oncol 51:307–310PubMedCrossRef
5.
Zurück zum Zitat Hampl M, Deckers-Figiel S, Hampl JA et al (2008) New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 109:340–345PubMedCrossRef Hampl M, Deckers-Figiel S, Hampl JA et al (2008) New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 109:340–345PubMedCrossRef
6.
Zurück zum Zitat Hampl M, Ramp U, Bender HG, Kueppers V (2006) A case of a pT3, HPV 52-positive vulvar carcinoma in an 18-year-old woman. Gynecol Oncol 101:530–533PubMedCrossRef Hampl M, Ramp U, Bender HG, Kueppers V (2006) A case of a pT3, HPV 52-positive vulvar carcinoma in an 18-year-old woman. Gynecol Oncol 101:530–533PubMedCrossRef
7.
Zurück zum Zitat Jones RW, Baranyai J, Stables S (1997) Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 90:448–452PubMedCrossRef Jones RW, Baranyai J, Stables S (1997) Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 90:448–452PubMedCrossRef
8.
Zurück zum Zitat Joura EA, Losch A, Haider-Angeler MG et al (200) Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 45:613–615 Joura EA, Losch A, Haider-Angeler MG et al (200) Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 45:613–615
9.
Zurück zum Zitat Judson PL, Habermann EB, Baxter NN et al 82006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022 Judson PL, Habermann EB, Baxter NN et al 82006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022
10.
Zurück zum Zitat Messing MJ, Gallup DG (1995) Carcinoma of the vulva in young women. Obstet Gynecol 86:51–54PubMedCrossRef Messing MJ, Gallup DG (1995) Carcinoma of the vulva in young women. Obstet Gynecol 86:51–54PubMedCrossRef
11.
Zurück zum Zitat Hampl M, Wentzensen N, Vinokurova S et al (2007) Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol 133:235–245PubMedCrossRef Hampl M, Wentzensen N, Vinokurova S et al (2007) Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol 133:235–245PubMedCrossRef
12.
Zurück zum Zitat Hampl M, Sarajuuri H, Wentzensen N et al (2006) Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 108:1361–1368PubMedCrossRef Hampl M, Sarajuuri H, Wentzensen N et al (2006) Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 108:1361–1368PubMedCrossRef
13.
Zurück zum Zitat Jones RW, Rowan DM, Stewart AW (2005) Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106:1319–1326PubMedCrossRef Jones RW, Rowan DM, Stewart AW (2005) Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106:1319–1326PubMedCrossRef
14.
Zurück zum Zitat Seters M van, Beurden M van, Craen AJ de (2005) Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 97:645–651PubMedCrossRef Seters M van, Beurden M van, Craen AJ de (2005) Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 97:645–651PubMedCrossRef
15.
Zurück zum Zitat Zaloudek CRJ Differentiated vulva intraepithelial neoplasia (VIN) (2005) An unrecognised form of high grade VIN associated with keratinising squamous cell carcinoma of the vulva. Pathol Case Rev 10:35–40CrossRef Zaloudek CRJ Differentiated vulva intraepithelial neoplasia (VIN) (2005) An unrecognised form of high grade VIN associated with keratinising squamous cell carcinoma of the vulva. Pathol Case Rev 10:35–40CrossRef
16.
Zurück zum Zitat zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350CrossRef zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350CrossRef
17.
Zurück zum Zitat Baumann KH, Muller O, Naujok HB et al (2010) Small-area analysis of incidence and localisation of vulvar cancer. J Oncol 512032 Baumann KH, Muller O, Naujok HB et al (2010) Small-area analysis of incidence and localisation of vulvar cancer. J Oncol 512032
18.
Zurück zum Zitat Hampl M (2011) Vulvakarzinome der vorderen Kommissur-eine zunehmende Tumorentität. gyn 16 Hampl M (2011) Vulvakarzinome der vorderen Kommissur-eine zunehmende Tumorentität. gyn 16
19.
Zurück zum Zitat Schomann P (2007) Schnellwachsende, altersunabhängige, vulväre, erosive, subklitorale Neoplasien. gyn 12:69–76 Schomann P (2007) Schnellwachsende, altersunabhängige, vulväre, erosive, subklitorale Neoplasien. gyn 12:69–76
20.
Zurück zum Zitat Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT (1992) Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 79:490–497PubMed Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT (1992) Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 79:490–497PubMed
21.
Zurück zum Zitat Hampl M, Hantschmann P, Michels W, Hillemanns P (2008) Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol 111:282–288PubMedCrossRef Hampl M, Hantschmann P, Michels W, Hillemanns P (2008) Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol 111:282–288PubMedCrossRef
22.
Zurück zum Zitat Van der Zee AG, Oonk MH, De Hullu JA et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26:884–889CrossRef Van der Zee AG, Oonk MH, De Hullu JA et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26:884–889CrossRef
23.
Zurück zum Zitat Puig-Tintore LM, Ordi J, Vidal-Sicart S et al (2003) Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol Oncol 88:29–34PubMedCrossRef Puig-Tintore LM, Ordi J, Vidal-Sicart S et al (2003) Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol Oncol 88:29–34PubMedCrossRef
24.
Zurück zum Zitat Moore RG, Granai CO, Gajewski W et al (2003) Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecol Oncol 91:378–382PubMedCrossRef Moore RG, Granai CO, Gajewski W et al (2003) Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecol Oncol 91:378–382PubMedCrossRef
25.
Zurück zum Zitat Gaarenstroom KN, Kenter GG, Trimbos JB et al (2003) Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 13:522–527PubMedCrossRef Gaarenstroom KN, Kenter GG, Trimbos JB et al (2003) Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 13:522–527PubMedCrossRef
26.
Zurück zum Zitat Nestle-Krämling C, Janni W, Hampl M (2009) Defektdeckung an der Vulva mit plastisch-rekonstruktiven Verfahren – Indikationen, Techniken, Ergebnisse. Geburtsh Frauenheilk 69:1082–1090CrossRef Nestle-Krämling C, Janni W, Hampl M (2009) Defektdeckung an der Vulva mit plastisch-rekonstruktiven Verfahren – Indikationen, Techniken, Ergebnisse. Geburtsh Frauenheilk 69:1082–1090CrossRef
27.
Zurück zum Zitat Hockel M, Dornhofer N (2008) Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 9:559–568PubMedCrossRef Hockel M, Dornhofer N (2008) Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 9:559–568PubMedCrossRef
28.
Zurück zum Zitat Lister GD, Gibson T (1972) Closure of rhomboid skin defects: the flaps of Limberg and Dufourmentel. Br J Plast Surg 25:300–314PubMedCrossRef Lister GD, Gibson T (1972) Closure of rhomboid skin defects: the flaps of Limberg and Dufourmentel. Br J Plast Surg 25:300–314PubMedCrossRef
29.
Zurück zum Zitat Moschella F, Cordova A (2000) Innervated island flaps in morphofunctional vulvar reconstruction. Plast Reconstr Surg 105:1649–1657PubMedCrossRef Moschella F, Cordova A (2000) Innervated island flaps in morphofunctional vulvar reconstruction. Plast Reconstr Surg 105:1649–1657PubMedCrossRef
30.
Zurück zum Zitat Yii NW, Niranjan NS (1996) Lotus petal flaps in vulvo-vaginal reconstruction. Br J Plast Surg 49:547–554PubMedCrossRef Yii NW, Niranjan NS (1996) Lotus petal flaps in vulvo-vaginal reconstruction. Br J Plast Surg 49:547–554PubMedCrossRef
31.
Zurück zum Zitat Lindell G, Nasman A, Jonsson C et al (2010) Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. Gynecol Oncol 117:312–316PubMedCrossRef Lindell G, Nasman A, Jonsson C et al (2010) Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. Gynecol Oncol 117:312–316PubMedCrossRef
32.
Zurück zum Zitat Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044PubMedCrossRef Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044PubMedCrossRef
33.
Zurück zum Zitat Joura EA, Kjaer SK, Wheeler CM et al (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26:6844–6851PubMedCrossRef Joura EA, Kjaer SK, Wheeler CM et al (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26:6844–6851PubMedCrossRef
34.
Zurück zum Zitat Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170PubMedCrossRef Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170PubMedCrossRef
35.
Zurück zum Zitat Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 yrs of follow-up. Br J Cancer 95:1459–1466PubMedCrossRef Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 yrs of follow-up. Br J Cancer 95:1459–1466PubMedCrossRef
36.
Zurück zum Zitat Descamps D, Hardt K, Spiessens B et al (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5 Descamps D, Hardt K, Spiessens B et al (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5
37.
Zurück zum Zitat Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRef Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943PubMedCrossRef
38.
Zurück zum Zitat Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693–1702PubMedCrossRef Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693–1702PubMedCrossRef
39.
Zurück zum Zitat Paavonen J, Naud P, Salmeron J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314PubMedCrossRef Paavonen J, Naud P, Salmeron J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314PubMedCrossRef
40.
Zurück zum Zitat Monsonego J, Cortes J, Greppe C et al (2010) Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. Vaccine 28:8065–8072PubMedCrossRef Monsonego J, Cortes J, Greppe C et al (2010) Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. Vaccine 28:8065–8072PubMedCrossRef
41.
Zurück zum Zitat DGGG (2009) S2k-Leitlinie Diagnostik und Therapie des Vulvakarzinoms und seiner Vorstufen, S 28–29 DGGG (2009) S2k-Leitlinie Diagnostik und Therapie des Vulvakarzinoms und seiner Vorstufen, S 28–29
42.
Zurück zum Zitat Robert-Koch-Institut (2007) Epidemiologisches Bulletin vom 23.03.2007; 12, 97–103 Robert-Koch-Institut (2007) Epidemiologisches Bulletin vom 23.03.2007; 12, 97–103
43.
Zurück zum Zitat Ansitz A, van der Velden J (2000) Surgical intervention for early sqamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000 (2) Ansitz A, van der Velden J (2000) Surgical intervention for early sqamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000 (2)
44.
Metadaten
Titel
Vulvakarzinom – bei weitem kein ungefährliches Alterskarzinom
Moderne Therapieoptionen
verfasst von
Prof. Dr. M. Hampl
G. Bauerschmitz
W. Janni
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Die Gynäkologie / Ausgabe 9/2011
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-011-2767-x

Weitere Artikel der Ausgabe 9/2011

Die Gynäkologie 9/2011 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Die überaktive Blase

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.